Wedbush analyst Laura Chico lowered the firm’s price target on Denali Therapeutics to $38 from $46 and keeps an Outperform rating on the shares following quarterly results. The firm notes all key pipeline efforts remain on track, and says it is "most intrigued" by the OTV efforts and awaits further clarity on the strategy.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DNLI:
- 3 Stocks to Buy Today, 2/28/2023, According to Top Analysts
- Denali Therapeutics reports Q4 EPS (75c), consensus (79c)
- Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
- Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
